Sharp Therapeutics (TSXV:SHRX) Notes Receivable: C$0.00 Mil (As of Dec. 2025)


TSXV:SHRX Sharp Therapeutics Corp TSXV:SHRX
14 GF Score
Price C$0.91
View Full Analysis

What is Sharp Therapeutics Notes Receivable?

Sharp Therapeutics TSXV:SHRX 14 Notes Receivable is C$0.00 Mil as of Dec. 2025. GuruFocus rates TSXV:SHRX with a GF Score™ of 14/100.

Sharp Therapeutics's Notes Receivable for the quarter that ended in Dec. 2025 was C$0.00 Mil.

Sharp Therapeutics Notes Receivable Related Terms

Sharp Therapeutics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Sharp Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sharp Therapeutics Notes Receivable Chart

Sharp Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Notes Receivable
0.00 0.00 0.00

Sharp Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSXV:SHRX
14GF Score
Sharp Therapeutics Corp TSXV:SHRX
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sharp Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of C$0.00 Mil mean?
Sharp Therapeutics (TSXV:SHRX) has a Notes Receivable of C$0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Sharp Therapeutics and its competitors.
Is Sharp Therapeutics' Notes Receivable too high?
Sharp Therapeutics' current Notes Receivable is C$0.00 Mil. Overall, Sharp Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sharp Therapeutics' Notes Receivable compare to VRTX and REGN?
Sharp Therapeutics' Notes Receivable of C$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Sharp Therapeutics and its competitors. Sharp Therapeutics's current Notes Receivable is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sharp Therapeutics stock overvalued right now?
Sharp Therapeutics (TSXV:SHRX) has a current Notes Receivable of C$0.00 Mil. The current Notes Receivable is C$0.00 Mil. Sharp Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Sharp Therapeutics (TSXV:SHRX), the current Notes Receivable is C$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sharp Therapeutics Business Description

Address 2403 Sidney Street, Suite 264, Pittsburgh, PA, USA, 15203
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
14GF Score

Get the complete analysis for TSXV:SHRX

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.91
Price